Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 2Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Lung Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Head and Neck Neoplasms 30Urinary Bladder Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 17Esophageal Neoplasms 17Small Cell Lung Carcinoma 16Cholangiocarcinoma 16Neoplasm Metastasis 13Ovarian Neoplasms 12Carcinoma, Squamous Cell 11Breast Neoplasms 11Neoplasms 10Mesothelioma, Malignant 9Esophageal Squamous Cell Carcinoma 8Biliary Tract Neoplasms 8Sarcoma 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Mesothelioma 6Adenocarcinoma of Lung 6Adenocarcinoma Of Esophagus 6Recurrence 5Gallbladder Neoplasms 5Carcinoma, Ovarian Epithelial 5Bile Duct Neoplasms 5Triple Negative Breast Neoplasms 4Osteosarcoma 4

Interventions

Pemetrexed 3Carboplatin 3HM781-36B 2Gemcitabine 2pembrolizumab 1osimertinib 1aumolertinib 1aflutinib 1Taxes 1Paclitaxel 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cisplatin 1Bortezomib 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC × Cisplatin × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡